NASDAQ:CDMO

Avid Bioservices Competitors

$19.39
-0.56 (-2.81 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.36
Now: $19.39
$20.31
50-Day Range
$16.01
MA: $18.25
$21.77
52-Week Range
$3.95
Now: $19.39
$22.13
Volume292,666 shs
Average Volume797,130 shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Competitors

Avid Bioservices (NASDAQ:CDMO) Vs. AVIR, SAGE, BHVN, HCM, EBS, and ARNA

Should you be buying CDMO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Avid Bioservices, including Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), and Arena Pharmaceuticals (ARNA).

Atea Pharmaceuticals (NASDAQ:AVIR) and Avid Bioservices (NASDAQ:CDMO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Atea Pharmaceuticals and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Avid Bioservices0.20%0.31%0.13%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Atea Pharmaceuticals and Avid Bioservices, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Avid Bioservices00303.00

Atea Pharmaceuticals currently has a consensus target price of $69.3333, indicating a potential upside of 22.69%. Avid Bioservices has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Avid Bioservices.

Valuation & Earnings

This table compares Atea Pharmaceuticals and Avid Bioservices' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81

Atea Pharmaceuticals has higher earnings, but lower revenue than Avid Bioservices.

Summary

Avid Bioservices beats Atea Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Avid Bioservices (NASDAQ:CDMO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sage Therapeutics and Avid Bioservices, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Avid Bioservices00303.00

Sage Therapeutics currently has a consensus target price of $87.0625, indicating a potential upside of 13.64%. Avid Bioservices has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Given Sage Therapeutics' higher probable upside, analysts plainly believe Sage Therapeutics is more favorable than Avid Bioservices.

Valuation & Earnings

This table compares Sage Therapeutics and Avid Bioservices' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million651.04$-680,240,000.00($13.38)-5.73
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81

Avid Bioservices has higher revenue and earnings than Sage Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sage Therapeutics and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Avid Bioservices0.20%0.31%0.13%

Risk and Volatility

Sage Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.

Insider and Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by insiders. Comparatively, 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Avid Bioservices beats Sage Therapeutics on 9 of the 14 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Avid Bioservices and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Biohaven Pharmaceutical021002.83

Avid Bioservices currently has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Biohaven Pharmaceutical has a consensus target price of $96.4545, indicating a potential upside of 39.00%. Given Biohaven Pharmaceutical's higher probable upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Avid Bioservices.

Earnings and Valuation

This table compares Avid Bioservices and Biohaven Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.36

Avid Bioservices has higher revenue and earnings than Biohaven Pharmaceutical. Avid Bioservices is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avid Bioservices and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Volatility and Risk

Avid Bioservices has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Avid Bioservices beats Biohaven Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Avid Bioservices and Hutchison China MediTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Hutchison China MediTech00203.00

Avid Bioservices currently has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Hutchison China MediTech has a consensus target price of $40.00, indicating a potential upside of 36.80%. Given Hutchison China MediTech's higher probable upside, analysts plainly believe Hutchison China MediTech is more favorable than Avid Bioservices.

Earnings and Valuation

This table compares Avid Bioservices and Hutchison China MediTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55

Avid Bioservices has higher earnings, but lower revenue than Hutchison China MediTech. Avid Bioservices is trading at a lower price-to-earnings ratio than Hutchison China MediTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avid Bioservices and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
Hutchison China MediTechN/AN/AN/A

Volatility and Risk

Avid Bioservices has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Avid Bioservices beats Hutchison China MediTech on 9 of the 13 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Avid Bioservices and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Emergent BioSolutions02502.71

Avid Bioservices currently has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Emergent BioSolutions has a consensus target price of $109.8333, indicating a potential upside of 42.00%. Given Emergent BioSolutions' higher probable upside, analysts plainly believe Emergent BioSolutions is more favorable than Avid Bioservices.

Earnings and Valuation

This table compares Avid Bioservices and Emergent BioSolutions' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81
Emergent BioSolutions$1.11 billion3.73$54.50 million$2.9126.58

Emergent BioSolutions has higher revenue and earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avid Bioservices and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
Emergent BioSolutions12.50%26.68%12.70%

Volatility and Risk

Avid Bioservices has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Insider & Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Emergent BioSolutions beats Avid Bioservices on 11 of the 14 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Avid Bioservices and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Arena Pharmaceuticals001503.00

Avid Bioservices currently has a consensus target price of $17.3333, indicating a potential downside of 10.61%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 38.48%. Given Arena Pharmaceuticals' higher probable upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Avid Bioservices.

Earnings and Valuation

This table compares Avid Bioservices and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81
Arena Pharmaceuticals$806.43 million4.96$397.55 million$7.698.62

Arena Pharmaceuticals has higher revenue and earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avid Bioservices and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
Arena PharmaceuticalsN/A-33.17%-30.41%

Volatility and Risk

Avid Bioservices has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

58.2% of Avid Bioservices shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Arena Pharmaceuticals beats Avid Bioservices on 8 of the 13 factors compared between the two stocks.


Avid Bioservices Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.